GlassScriptPhysician profile
Anil Kumar Badhwar
NPI 1992764260
$6,986.98
in general payments reported to CMS, 2019-2025
31 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $216 · 2021: $320 · 2022: $836 · 2023: $1,163 · 2024: $1,506 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.02 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,148.43 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,064.72 | 2019-2025 | Nucala, Arexvy |
| Amgen INC. | $835.95 | 2022-2025 | Krystexxa, Tezspire, Tavneos |
| Regeneron Healthcare Solutions, INC. | $348.94 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $301.43 | 2023-2025 | Nuzyra |
| Blueprint Medicines Corporation | $271.02 | 2022-2025 | Ayvakit |
| Phathom Pharmaceuticals, INC. | $197.56 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $193.37 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $169.22 | 2025 | Neffy |
| Abbott Laboratories | $158.12 | 2019 | |
| Phadia US INC. | $150.29 | 2024 | Immunocap |
| Ucb, INC. | $146.52 | 2025 | |
| Genzyme Corporation | $145.19 | 2019-2025 | |
| Genentech USA, INC. | $140.11 | 2022-2024 | Xolair |
| Gilead Sciences, INC. | $125.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Grifols USA, LLC | $95.08 | 2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.88 | 2019-2024 | |
| Pharming Healthcare, INC. | $91.14 | 2023 | Joenja |
| Janssen Pharmaceuticals, INC | $64.29 | 2019 | |
| Aimmune Therapeutics, INC. | $33.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.97 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.48 | 2024 | Xifaxan, Trulance |
| Kiniksa Pharmaceuticals, LTD. | $20.34 | 2021 | |
| Hikma Pharmaceuticals USA | $19.56 | 2024 | Ryaltris |
| Csl Behring | $14.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.93 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Badhwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.